Deutsche Bank Ag\ Immuneering Corp Transaction History

Deutsche Bank Ag\

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.91 - $7.32 $882 - $3,381	-462 Reduced 3.9%	11,382 $32,000
Q3 2023 Nov 09, 2023	BUY	$7.21 - $10.68 $77,817 - $115,269	10,793 Added 1026.93%	11,844 $90,000
Q2 2023 Aug 14, 2023	BUY	$6.49 - $13.36 $6,820 - $14,041	1,051 New	1,051 $10,000
Q2 2022 Aug 11, 2022	SELL	$3.89 - $7.81 $40,619 - $81,552	-10,442 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $35,067 - $92,085	5,420 Added 107.93%	10,442 $68,000
Q4 2021 Feb 11, 2022	BUY	$16.12 - $31.02 $4,352 - $8,375	270 Added 5.68%	5,022 $81,000
Q3 2021 Nov 04, 2021	BUY	$17.0 - $32.84 $80,784 - $156,055	4,752 New	4,752 $126,000

9.65M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $70.2M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.